Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Using Hematoxylin-eosin (H&E) and Oil Red O staining, we found that CCDC80 overexpression in vivo significantly increased plasma lipid contents, decreased the expression and activity of lipoprotein lipase (LPL), and accelerated the development of atherosclerosis.
|
30439364 |
2019 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Krüppel-like factor 14 inhibits atherosclerosis via mir-27a-mediated down-regulation of lipoprotein lipase expression in vivo.
|
31518965 |
2019 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-27 prevents atherosclerosis by inhibiting inflammatory responses induced by lipoprotein lipase.
|
31169351 |
2019 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, nobiletin may alleviate lipid accumulation and secretion of pro-inflammatory cytokines by enhancing the inhibitory effect of miR-590 on LPL expression, suggesting a promising strategy for potential drug development for atherosclerosis.
|
30471854 |
2019 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We showed that VLDL remnants are the major atherogenic lipoproteins in the postprandial plasma associated with insufficient LPL activity and a causal factor in the initiation and progression of atherosclerosis.
|
29307667 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The role of LPL in atherosclerosis is still controversial as reported in the literature.
|
29453968 |
2018 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphism (SNP) in lipoprotein lipase (LPL) gene (rs1801177) is strongly associated with the increased progression of atherosclerosis, threatening global public health.
|
29175215 |
2018 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
VLDL remnants have been shown as the major atherogenic lipoproteins in postprandial plasma associated with LPL activity as the targets for prevention of atherosclerosis.
|
29493553 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrate that LPL gene plays a major role in extreme HTG associated with hyperchylomicronemia, although the condition may not cause severe atherosclerosis.
|
29153744 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, muscle and macrophage LpL have opposite effects on atherosclerosis.
|
29419410 |
2018 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is concluded that miR-377 upregulates GPIHBP1 expression, increases the LPL binding to GPIHBP1, and reduces plasma triglyceride levels, likely through targeting DNMT1, inhibiting atherosclerosis in ApoE-KO mice.
|
30232292 |
2018 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Macrophage lipoprotein lipase (LPL) induces lipid accumulation and promotes atherosclerosis.
|
28205069 |
2017 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Previous studies have shown that miR-467b plays a central role in the progression of atherosclerosis via regulating LPL expression.
|
27678191 |
2017 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Postprandial lipemia and lipoprotein lipase (LPL) activity play crucial roles in the pathogenesis of accelerated atherosclerosis.
|
28814963 |
2017 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoprotein lipase (LPL) expressed in macrophages plays an important role in promoting the development of atherosclerosis or atherogenesis.
|
28855441 |
2017 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previous researches have indicated that macrophage-derived lipoprotein lipase (LPL) promotes atherosclerosis progression by accelerating lipid accumulation and pro-inflammatory cytokine secretion.
|
28444107 |
2017 |
Atherosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
However, it has not been fully understood whether miR-27 affects the expression of LPL and subsequent development of atherosclerosis in apolipoprotein E knockout (apoE KO) mice.
|
27257686 |
2016 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects on changes of LPL and EL mass differed depending on the lipid-lowering therapy, which may impact the prevention of atherosclerosis differently.
|
27039080 |
2016 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
LPL with different distributions may exert distinct functions and have diverse roles in human health and disease with close association with atherosclerosis.
|
25463094 |
2014 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, macrophage LPL was reported to promote foam cell formation and atherosclerosis in vivo.
|
22772754 |
2012 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 60-y-old chylomicronemia patient homozygous for missense mutation (G188E) in the lipoprotein lipase gene showed no accelerated atherosclerosis.
|
17854791 |
2008 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, transgenic mice expressing catalytically active or inactive LPL developed the same extent of atherosclerosis.
|
17761930 |
2007 |
Atherosclerosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
LPL may influence atherosclerosis risk through pleiotropic effects on each aspect of the metabolic syndrome.
|
16755277 |
2007 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prior studies of Mexican Americans described association of lipoprotein lipase (LPL) gene haplotypes with insulin sensitivity/resistance and atherosclerosis.
|
17032721 |
2007 |
Atherosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The data show that transgenic hLPL(S447X) on top of endogenous murine LPL reduces fasting TG levels in plasma but has no effect on atherosclerosis in LDLr-/- mice.
|
17087965 |
2007 |